;

Diabetes and hypertension are silent threats to Thai health and key risk factors for cardiovascular and chronic kidney diseases. Data from 2024 shows 33,976 patients began kidney replacement therapy, while the 7th Thai National Health Examination Survey (2024–2025) found that 27.0% of adults with diabetes and 47.8% with hypertension were previously undiagnosed.
These findings reveal critical gaps in early detection, diagnosis, and care for at-risk individuals. Without proper and continuous management, severe complications may develop, increasing burdens on the healthcare system and the economy over time.
In response, the Pharmaceutical Researchers and Manufacturers Association (PReMA) emphasizes the need to adjust approaches to non-communicable diseases (NCDs) by focusing on integrated care for heart, kidney, and diabetes conditions, given their shared risk factors and interrelated system effects.
Health management should not isolate diseases but consider patients holistically—from risk assessment and abnormality detection to ongoing care—under the “Frontier of Hope” concept, reflecting advances in science and medical innovation that can improve long-term patient care and quality of life.
Medical progress is shifting diabetes care from solely controlling blood sugar to comprehensive management aimed at reducing long-term complications and protecting vital organs, especially heart and kidneys. Thailand’s 2024 kidney replacement therapy registry reports diabetes and hypertension as leading causes of end-stage kidney disease.
Mr. Cihan Serdar Kizilcik, PReMA Vice President and General Manager of Novo Thailand, stated that diabetes care goals now extend beyond blood sugar and BMI control to holistic health, including heart and kidney protection. For those diagnosed at age 50, proper care today can improve life quality and longevity, allowing more meaningful years with family.
Thailand’s main challenge is not only early risk identification and diagnosis but also ensuring patients receive timely, appropriate, and continuous care to reduce complications and maintain long-term disease control.
Mr. Ricarte Cervantes Rivera, Co-Chair of PReMA’s Early Intervention Policy Working Group and General Manager and Head of Human Pharmaceuticals at Boehringer Ingelheim (Thailand), said Thailand has potential to enhance NCD care by building on existing health service systems.
By leveraging scientific knowledge, health data, and digital technology, patient care efficiency can improve. Today, combined urine and blood tests can detect kidney damage and assess function and disease risk. New methods and tools require clinical evidence evaluation and adaptation to Thailand’s context.
Beyond health impacts, NCDs impose a significant economic burden on Thailand, estimated at 1.6 trillion baht annually or 9.7% of GDP based on 2019 data, mostly from productivity losses due to illness and premature death.
An investment model estimates that spending around 211 billion baht on NCD management could generate economic benefits of up to 430 billion baht over 15 years and potentially save about 310,000 lives.
These economic and life-saving projections are modeled estimates for overall NCD prevention and care, not actual results, based on the 2021 WHO report "Prevention and Control of Noncommunicable Diseases in Thailand: The Case for Investment," prepared with UNDP and the Ministry of Public Health.
Mr. Harald Sprenger, CEO of PReMA, said improving NCD management requires cooperation from all sectors—government, healthcare professionals, academia, industry, and budget and health benefit stakeholders—to link scientific evidence, research, and health innovation with policy development and service systems suited to Thailand’s context.
Mr. Harald added that Thailand plays a key role in advancing the APEC Cardiovascular Health Roadmap 2026–2030, a regional collaboration framework for cardiovascular health. PReMA plans a Policy Dialogue in March 2027 to provide a platform for policymakers, medical personnel, academics, patient representatives,
and related sectors to exchange knowledge and perspectives, jointly seeking ways to promote early-stage screening, diagnosis, and continuous, appropriate care, as well as integrating scientific evidence into health policy development tailored to Thailand’s context.
Such collaboration will be an important step toward enhancing heart, kidney, and diabetes care for Thais, aiming to build a stronger, more sustainable health system.